Cargando…
Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder
Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder with few medication options. Bumetanide, an FDA-approved diuretic, has been proposed as a viable candidate to treat core symptoms of ASD, however, neither the brain region related to its effect nor the cell-specific mechanism(...
Autores principales: | Lv, Hui, Gu, Xiao, Shan, Xingyue, Zhu, Tailin, Ma, Bingke, Zhang, Hao-Tian, Bambini-Junior, Victorio, Zhang, Tiantian, Li, Wei-Guang, Gao, Xiaoling, Li, Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179025/ https://www.ncbi.nlm.nih.gov/pubmed/35693812 http://dx.doi.org/10.3389/fimmu.2022.870577 |
Ejemplares similares
-
The Impact of Neuroimmune Alterations in Autism Spectrum Disorder
por: Gottfried, Carmem, et al.
Publicado: (2015) -
Treatment Effect of Bumetanide in Children With Autism Spectrum Disorder: A Systematic Review and Meta-Analysis
por: Wang, Tiantian, et al.
Publicado: (2021) -
The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder
por: Li, Qingyang, et al.
Publicado: (2022) -
The effects of aging on the BTBR mouse model of autism spectrum disorder
por: Jasien, Joan M., et al.
Publicado: (2014) -
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
por: Lemonnier, E, et al.
Publicado: (2017)